-
Drugs 2008Doripenem, a parenteral, broad-spectrum antibacterial agent of the carbapenem family, is indicated as empirical therapy in serious bacterial infections in adults.... (Review)
Review
Doripenem, a parenteral, broad-spectrum antibacterial agent of the carbapenem family, is indicated as empirical therapy in serious bacterial infections in adults. Doripenem is indicated in Japan for use as a single agent in intra-abdominal infections (IAIs), lower respiratory tract infections (including nosocomial pneumonia), complicated urinary tract infections (cUTIs) and a variety of other bacterial infections, such as complicated skin and skin structure infections (cSSSIs), obstetric and gynaecological infections, serious ear, nose and throat infections, sepsis and endocarditis, dental and oral surgical infection, and ophthalmic infection caused by various susceptible strains of Gram-negative, Gram-positive or anaerobic bacteria. Doripenem is indicated in the US for the treatment of complicated IAIs (cIAIs) or cUTIs, including pyelonephritis, caused by susceptible strains of designated pathogens, and in the EU for the treatment of nosocomial pneumonia (including ventilator-associated pneumonia [VAP]), cIAIs or cUTIs.Doripenem has a broad spectrum of in vitro activity against Gram-positive and Gram-negative bacteria, including extended-spectrum beta-lactamase (ESBL)- and AmpC-producing Enterobacteriaceae, and anaerobic pathogens. The drug also has a low propensity to select for resistance and is suitable for the prolonged infusions that may be required to achieve pharmacodynamic/pharmacokinetic targets for bactericidal activity (and therefore efficacy) against pathogens with increased MICs (minimum concentrations required to inhibit the pathogens). Doripenem is no less effective than other antibacterial agents, including meropenem, imipenem/cilastin, piperacillin/tazobactam or levofloxacin in a wide range of serious bacterial infections, such as complicated lower respiratory infections, nosocomial pneumonia (including VAP), cIAIs and cUTIs, and is well tolerated. Thus, doripenem is a valuable addition to the options available for the empirical treatment of serious bacterial infections in hospitalized patients.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Doripenem; Drug Interactions; Drug Resistance, Bacterial; Humans; Kidney Diseases; Tissue Distribution
PubMed: 18778123
DOI: 10.2165/00003495-200868140-00007 -
Infection Control and Hospital... May 1988
Review
Topics: Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomena; Chemistry; Glycopeptides; Gram-Positive Bacteria; Humans; Teicoplanin
PubMed: 2967322
DOI: 10.1086/645836 -
Croatian Medical Journal Feb 2011To study the antimicrobial activity of citric acid (CA) and sodium hypophosphite monohydrate (SHP) against gram-positive and gram-negative bacteria, and to determine the...
AIM
To study the antimicrobial activity of citric acid (CA) and sodium hypophosphite monohydrate (SHP) against gram-positive and gram-negative bacteria, and to determine the influence of conventional and microwave thermal treatments, on the effectiveness of antimicrobial treatment of cotton textiles.
METHOD
Textile material was impregnated with CA and SHP solution and thermally treated by either conventional or microwave drying/curing treatment. Antibacterial effectiveness was tested according to ISO 20743:2009 standard, using absorption method. The surfaces were morphologically observed by scanning electron microscopy, while physical characteristics were determined by wrinkle recovery angles method (DIN 53 891), tensile strength (DIN 53 837), and whiteness degree method (AATCC 110-2000).
RESULTS
Cotton fabric treated with CA and SHP showed significant antibacterial activity against MRSA (6.38 log10 treated by conventional drying and 6.46 log10 treated by microwave drying before washing, and 6.90 log10 and 7.86 log10, respectively, after 1 cycle of home domestic laundering washing [HDLW]). Antibacterial activity was also remarkable against S. aureus (4.25 log10 by conventional drying, 4.58 log10 by microwave drying) and against P. aeruginosa (1.93 log10 by conventional drying and 4.66 log10 by microwave drying). Antibacterial activity against P. aeruginosa was higher in samples subjected to microwave than in conventional drying. Antibacterial activity was reduced after 10 HDLW cycles but the compound was still effective. The surface of the untreated cotton polymer was smooth, while minor erosion stripes appeared on the surfaces treated with antimicrobial agent, and long and deep stripes were found on the surface of the washed sample.
CONCLUSION
CA can be used both for the disposable (non-durable) materials (gowns, masks, and cuffs for blood pressure measurement) and the materials that require durability to laundering. The current protocols and initiatives in infection control could be improved by the use of antimicrobial agents applied on cotton carbohydrate polymer.
Topics: Anti-Bacterial Agents; Carbohydrates; Citric Acid; Cotton Fiber; Cross Infection; Drug Carriers; Drug Delivery Systems; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infection Control; Materials Testing; Pharmaceutical Solutions; Phosphinic Acids; Polymers; Technology, Pharmaceutical; Textiles; Treatment Outcome
PubMed: 21328723
DOI: 10.3325/cmj.2011.52.68 -
Pharmacological Reports : PR Dec 2016Mycobacterium tuberculosis (Mtb) is considered as one of the precarious bacterial infections around the world. Through a projected 8.7 million new tuberculosis (TB)... (Review)
Review
Mycobacterium tuberculosis (Mtb) is considered as one of the precarious bacterial infections around the world. Through a projected 8.7 million new tuberculosis (TB) cases and 1.4 million mortalities per annum, this deadly infection resulted insubstantial amount of human deaths than any other single organism bacterial infections. TB is one of India's most threatening human health problems and it accounts for approximately 33% of the global health issues. Subsequently, for TB there is an imperative need for the improvement of existing drug candidates with newer targets and specified mechanism of action. Within the wide spectra of heterocycles, benzimidazole and its substituted analogues were evidenced promising biological efficacies enabling them to perform as new drug or prodrug candidates. Exceptional structural features of this class of heterocycle and versatile biological applications made it a privileged structural backbone in new drug design and discovery. Majorly, 2,5- and 2,6-disubstituted benzimidazole derivatives shown to induce significant antiTB potential. To seek more insights on this unique feature of benzimidazole candidates, there is an urgency to assemble the recent advances in this promising area. This review presents an overview of the recent advancements and focuses on the structural features responsible for unique antiTB applications and compiled published reports on benzimidazole derivatives emphasizing on different approaches employed for their syntheses in order to help medicinal and clinical chemists in designing next generation, yet effective and safer antiTB candidates.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Benzimidazoles; Drug Design; Humans; Mycobacterium tuberculosis; Tuberculosis
PubMed: 27686965
DOI: 10.1016/j.pharep.2016.08.002 -
Current Drug Delivery 2018Recent advances in the field of bionanomedicine not only enable us to produce biomaterials but also to manipulate them at molecular level. Viruses particularly... (Review)
Review
BACKGROUND
Recent advances in the field of bionanomedicine not only enable us to produce biomaterials but also to manipulate them at molecular level. Viruses particularly bacteriophages are a promising nanomaterial that can be functionalized with great precision. Bacteriophages are the natural antimicrobial agents that fight against antibiotic resistant bacteria which cause infections in animals, humans, or in crops of agricultural value. The idea of utilizing bacteriophages as therapeutic agents is due to their ability to kill bacteria at the end of the infectious cycle.
OBJECTIVE
This paper reviewed the general biology of bacteriophages and the presence of receptors on the bacteria which are necessary for the recognition and adsorption of bacteriophages. Pharmacokinetics and therapeutic potential of bacteriophages administered through various routes in treating diverse bacterial infections is also reviewed along with the problems associated with bacteriophage therapy.
CONCLUSION
Among various routes of administration, parenteral route is found to be the most thriving route for the treatment of systemic infections whereas oral route is meant to treat gastrointestinal infections and; local delivery (skin, nasal, ears) of phages has proven its potency to treat topical infections.
Topics: Adsorption; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bacteriophages; Drug Resistance, Bacterial; Humans; Nanostructures; Phage Therapy; Surface Properties
PubMed: 27048165
DOI: 10.2174/1567201813666160406115744 -
ACS Infectious Diseases Feb 2023Novel antimicrobial agents with potent bactericidal activity are needed to treat infections caused by multidrug-resistant (MDR) extracellular pathogens, such as ....
Novel antimicrobial agents with potent bactericidal activity are needed to treat infections caused by multidrug-resistant (MDR) extracellular pathogens, such as . Antimicrobial peptides (AMPs) and peptidomimetics are promising alternatives to traditional antibiotics, but their therapeutic use is limited due to the lack of specificity and resulting off-target effects. The incorporation of an antibody into the drug design would alleviate these challenges by localizing the AMP to the target bacterial cells. Antibody-drug conjugates (ADCs) have already achieved clinical success as anticancer therapeutics, due to the ability of the antibody to deliver the payload directly to the cancer cells. This strategy involves the selective delivery of highly cytotoxic drugs to the target cells, which enables a broad therapeutic window. This platform can be translated to the treatment of infections, whereby an antibody is used to deliver an antimicrobial agent to the bacterial antigen. Herein, we propose the development of an antibody-bactericide conjugate (ABC) in which the antibacterial oligothioetheramide (oligoTEA), BDT-4G, is coupled to an anti- antibody via a cleavable linker. The drug BDT-4G was chosen based on its efficacy against a range of isolates and its ability to evade mechanisms conferring resistance to the last-resort agent polymyxin B. We demonstrate that the ABC binds to the bacterial cell surface, and following cleavage of the peptide linker, the oligoTEA payload is released and exhibits antipseudomonal activity.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Polymyxin B; Antineoplastic Agents; Antibodies
PubMed: 36626184
DOI: 10.1021/acsinfecdis.2c00492 -
Journal of Biomolecular Structure &... Jun 2021Here we report the electrospinning synthesis of Cd-substituted Ni-Co ferrite ( ≤ 0.25) nanofiber (NFs) with a very low concentration of Nd as a dopant. The...
Here we report the electrospinning synthesis of Cd-substituted Ni-Co ferrite ( ≤ 0.25) nanofiber (NFs) with a very low concentration of Nd as a dopant. The structure and surface morphology of the were analyzed by X-ray powder pattern (XRD), transmission and scanning electron microscopes (TEM) along with Energy-dispersive X-ray (EDX). We have examined the biological applications of the on both cancerous cells and bacterial cells. We have found that produced inhibitory action on the human colorectal carcinoma cells (HEK-293) and also showed inhibitory action on the bacterial strains () respectively. Finally, this is the first report on the synthesis of Cd- substituted Co-Ni ferrite nanofibers using electrospinning technique exhibiting anti-cancer and anti-bacterial activities.Communicated by Ramaswamy H. Sarma.
Topics: Anti-Bacterial Agents; Cadmium; Escherichia coli; HEK293 Cells; Humans; Nanofibers; Staphylococcus aureus
PubMed: 32340569
DOI: 10.1080/07391102.2020.1761880 -
Antimicrobial Agents and Chemotherapy Nov 1991
Review
Topics: Animals; Anti-Bacterial Agents; Humans; Pseudomonas Infections
PubMed: 1803987
DOI: 10.1128/AAC.35.11.2167 -
Nature Reviews. Microbiology Dec 2021
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Respiratory Tract Infections
PubMed: 34594016
DOI: 10.1038/s41579-021-00647-z -
Macromolecular Bioscience Oct 2021Chronic wound infections have caused an increasing number of deaths and economic burden, which necessitates wound treatment options. Hitherto, the development of... (Review)
Review
Chronic wound infections have caused an increasing number of deaths and economic burden, which necessitates wound treatment options. Hitherto, the development of functional wound dressings has achieved reasonable progress. Antibacterial agents, growth factors, and miRNAs are incorporated in different wound dressings to treat various types of wounds. As an effective antimicrobial agent and emerging wound healing therapeutic, antimicrobial peptides (AMPs) have attracted significant attention. The present study focuses on the application of AMPs in wound healing and discusses the types, properties and formulation strategies of AMPs used for wound healing. In addition, the clinical trial and the current status of studies on "antimicrobial peptides and wound healing" are elaborated through bibliometrics. Also, the challenges and opportunities for further development and utilization of AMP formulations in wound healing are discussed.
Topics: Anti-Bacterial Agents; Antimicrobial Peptides; Bandages; Humans; Wound Healing; Wound Infection
PubMed: 34405955
DOI: 10.1002/mabi.202100103